Key clinical point: Single nucleotide polymorphisms (SNPs) in the major multidrug resistance (MDR)-ATP-binding cassette (ABC) transporter genes, ABCB1, ABCC2, and ABCG2, influenced the achievement of molecular response (MR)3 and MR4 in patients with chronic-phase chronic myeloid leukemia (CML-CP) treated with nilotinib.
Major finding: Patients with ABCB1 rs1045642 TT ( P = .01) or ABCC2 rs3740066 CT ( P = .004) and CC ( P = .02) genotypes achieved significantly higher rates of MR3 in a shorter period. Conversely, patients with ABCG2 rs2231137 GG genotype had a lower probability of achieving MR3 ( P = .005). ABCC2 rs3740066 CC ( P = .02) and ABCB1 rs1045642 CC ( P = .007) and TT ( P = .003) genotypes were associated with higher rates of MR4 achievement.
Study details: This observational study assessed 7 SNPs in 4 ABC transporter genes ( ABCB1, ABCC1, ABCC2 , and ABCG2) in 90 Caucasian adult patients with CML-CP treated with first-or second-line nilotinib.
Disclosures: This study was supported in part by AIL Pesaro Onlus. The authors declared no conflicts of interest.
Source: Loscocco F et al. Front Oncol. 2021 May 13. doi: 10.3389/fonc.2021.672287 .